TotalSeq™-D Multiple Myeloma Antibody Cocktail

Multiple Myeloma is a complex and evolving disease where both genetic mutations and shifts in surface immunophenotype play critical roles in therapy response and resistance. Emerging precision therapies, such as CAR-T and bispecific antibodies, target these proteins, but resistance mechanisms involve genetic alterations that can alter their expression. By combining single-cell DNA and protein profiling, researchers can simultaneously map clonal architecture and immunophenotypic diversity, enabling a deeper understanding of disease progression and optimizing strategies for targeted immunotherapy.

Panel Details

The TotalSeq-D Multiple Myeloma Antibody Cocktail has been designed to react with 19 unique cell surface antigens, including key surface antigen makers for cell type classification and therapeutic target identification for multiple myeloma. The antibodies in the cocktail are provided at optimized concentrations to provide a ready-to-use solution.

View and download panel content and coordinates using Tapestri Designer

Have novel applications?

Our team of experts is ready to support requests for custom oligo-conjugated antibodies from BioLegend. Tell us about your targets of interest.

GET STARTED

Questions?

Our experts are standing by to help you find the right solution.

TALK TO A SCIENTIST

TotalSeq™-D Multiple Myeloma Antibody Cocktail

Panel Details

Have novel applications?

Other Pre-designed Panel Panels

Featured Resources

Questions?